{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:13:41Z","timestamp":1777565621051,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vascn.2022.107229","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T20:07:22Z","timestamp":1668024442000},"page":"107229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Determination of five positive control drugs in hERG external solution (buffer) by LC-MS\/MS to support in vitro hERG assay as recommended by ICH S7B"],"prefix":"10.1016","volume":"118","author":[{"given":"Tamara I.","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amruta","family":"Indapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isra","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"DePalma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabyasachy","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Alvarez-Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omnia A.","family":"Ismaiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali K.","family":"Matta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2022.107229_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2022.107193","article-title":"hERG block potencies for 5 positive control drugs obtained per ICH E14\/S7B Q&as best practices: Impact of recording temperature and drug loss","author":"Alvarez Baron","year":"2022","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2022.107229_bb0010","author":"Anonymous"},{"key":"10.1016\/j.vascn.2022.107229_bib82","first-page":"537","volume":"47","author":"Campanero","year":"1998"},{"issue":"3","key":"10.1016\/j.vascn.2022.107229_bb0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.vascn.2009.12.005","article-title":"Reduction of non-specific adsorption of drugs to plastic containers used in bioassays or analyses","volume":"61","author":"Fukazawa","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2022.107229_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.vascn.2022.107229_bb0025","series-title":"The clinical evaluation of QT\/QTC interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs","author":"ICH E14","year":"2005"},{"key":"10.1016\/j.vascn.2022.107229_bb0030","series-title":"Questions and answers: Clinical and nonclinical evaluation of QT\/QTc interval prolongation and Proarrhythmic potential","author":"ICH E14\/S7B IWG","year":"2022"},{"key":"10.1016\/j.vascn.2022.107229_bb0035","series-title":"The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","author":"ICH S7B","year":"2005"},{"issue":"2","key":"10.1016\/j.vascn.2022.107229_bib90","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jat\/bkz047","article-title":"Novel High-Throughput Quantitation of Potent hERG Blocker Dofetilide in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry: Application in a Phase 1 ECG Biomarker Validation Study","volume":"44","author":"Matta","year":"2019","journal-title":"Journal of Analytical Toxicology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107229_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2005.02.003","article-title":"A novel predictive pharmacokinetic\/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node--ablated, His bundle-paced dog","volume":"53","author":"Nolan","year":"2006","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2022.107229_bb0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107229_bb0045","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicological Sciences"},{"issue":"1","key":"10.1016\/j.vascn.2022.107229_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"issue":"7083","key":"10.1016\/j.vascn.2022.107229_bb0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vascn.2022.107229_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2017.11.002","article-title":"Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment","volume":"90","author":"Schocken","year":"2018","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2022.107229_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/1872312808666141127113055","article-title":"A systematic evaluation of solubility enhancing excipients to enable the generation of permeability data for poorly soluble compounds in Caco-2 model","volume":"8","author":"Shah","year":"2014","journal-title":"Drug Metabolism Letters"},{"issue":"3","key":"10.1016\/j.vascn.2022.107229_bb0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40264-013-0016-z","article-title":"Dealing with global safety issues\u202f: Was the response to QT-liability of non-cardiac drugs well coordinated?","volume":"36","author":"Stockbridge","year":"2013","journal-title":"Drug Safety"},{"key":"10.1016\/j.vascn.2022.107229_bib88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2019.04.041","article-title":"Development and validation of a UPLC-MS\/MS analytical method for dofetilide in mouse plasma and urine, and its application to pharmacokinetic study","volume":"172","author":"Uddin","year":"2019","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"1","key":"10.1016\/j.vascn.2022.107229_bb0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1476-5381.2009.00395.x","article-title":"Integrated risk assessment and predictive value to humans of non-clinical repolarization assays","volume":"159","author":"Wallis","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2022.107229_bib83","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/00498250110054632","article-title":"Pharmacokinetic\/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog","volume":"8","author":"Webster","year":"2001","journal-title":"Xenobiotica"},{"issue":"18","key":"10.1016\/j.vascn.2022.107229_bb0080","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/rcm.2102","article-title":"A study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays","volume":"19","author":"Xu","year":"2005","journal-title":"Rapid Communications in Mass Spectrometry"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:06:10Z","timestamp":1761005170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871922000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":21,"alternative-id":["S1056871922000764"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107229","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of five positive control drugs in hERG external solution (buffer) by LC-MS\/MS to support in vitro hERG assay as recommended by ICH S7B","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107229"}}